简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:Wockhardt shares surged by 14% today. How is it placed in the Pharma sector now
Wockhardt (NS:) shares jumped by 14% today as it completed the phase-3 pneumonia study of macrolide antibiotic Nafithromycin. However, if we talk about the valuations, as per InvestingPro+ some other companies in the Pharma sector may have more upside potential now. According to the Compare feature of InvestingPro+, Zydus Lifesciences Ltd (NS:) and Biocon (NS:) are attractively placed with potential upside of 24% and 21% respectively. Wockhardt, according to InvestingPro+ may have crossed its intrinsic value to be in the overvalued region now.
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.